25672 results about "Perylene derivatives" patented technology

The invention relates to a battery monomer, a battery device and a power utilization device, the battery monomer comprises an electrode assembly and an electrolyte, and the electrode assembly comprises a positive pole piece and a negative pole piece; the positive pole piece comprises a positive pole current collecting part and a positive pole film layer; the positive pole film layer comprises lithium-containing phosphate with an olivine structure; the negative pole piece comprises a negative pole current collecting part and a negative pole film layer, and the negative pole film layer comprises a carbon-based material; the electrolyte comprises a carboxylic ester solvent, a first additive and fluorine-containing lithium sulfimide, and the mass content of the carboxylic ester solvent is 8%-60%; the total mass content of the first additive is 2.5%-10%, the first additive comprises 1, 3-propane sultone with the mass content larger than or equal to 0, an ethylene carbonate derivative with the mass content larger than or equal to 0 and vinylene carbonate with the mass content larger than 0, and the ethylene carbonate derivative comprises a compound shown in the formula A; the mass content of the fluorine-containing lithium sulfimide is 4%-8%. According to the invention, the rapid charging performance and the cycle performance of the battery monomer can be improved. # imgabs0 # formula A

A benzo nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and a use thereof. Particularly, the present invention relates to a compound represented by general formula (XIX), a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, wherein each substituent in the general formula (XIX) is the same as the definition in the description.

The present invention discloses substituted 2-amino-9-(3,3-difluoropiperidin-4-yl)-7,9-dihydro-8H-purin-8-one compounds compounds having the structural formula represented by formula (I)： The substituted 2-amino-9-(3,3-difluoropiperidin-4-yl)-7,9-dihydro-8H-purin-8-one compounds, derivatives and pharmaceutically acceptable salts thereof of the present invention are capable of acting as a drug characteristic of a protein kinase inhibitor, in particular for the expression of a protein through a DNA-dependent protein kinase (DNA-PK) and can be used to treat or prevent disorders associated with abnormal protein kinase activity, such as cancer, cancer with brain metastases, cancer with meningeal metastases, glioma, glioblastoma, DIPG, and the like either as monotherapy or combination with other treatments, such as radiation therapy or chemotherapy.

Compounds are provided which can inhibit KRAS G12D. Also provided are pharmaceutical compositions and medical uses of the same, including the use in treating or preventing conditions such as cancers.

The invention provides a pyridopyrimidine derivative as a small GTP enzyme KRAS mutation inhibitor, and particularly provides a pyridopyrimidine derivative with a structural formula as shown in a general formula (A) and pharmaceutically acceptable salts thereof, and the pyridopyrimidine derivative has inhibitory activity on mutants such as KRAS G12D and the like. The invention also provides a preparation method of the derivative, a pharmaceutical composition and a salifying compound of the derivative, and medical application of the derivative as a small GTP enzyme KRAS mutation inhibitor in treatment of different types of tumors.

The invention belongs to the technical field of medicines, and particularly relates to quinazoline stilbene derivatives as well as a preparation method, a composition and application thereof. The quinazoline stilbene derivative is synthesized by combining quinazoline with pharmacophores such as a styrene skeleton, and the quinazoline stilbene derivative structurally contains functional units such as a quinazoline functional unit and the pharmacophores such as the styrene skeleton, so that the compound is endowed with good anti-tumor activity. Researches show that the quinazoline stilbene derivative has a good anti-tumor effect including KRASG12C mutation non-small cell lung cancer, has the advantage of multi-target action, has an adjusting effect on Src kinase and related downstream signal channels of Statat, mTOR, Akt and PI3k, and is beneficial to reduction of tumor drug resistance. Compared with a complex structure modified compound, the quinazoline stilbene derivative disclosed by the invention is simple in structure and easy to prepare, and has a good application prospect.

The present invention relates to an oxo-tricyclic derivative and the pharmaceutical use thereof, in particular to a compound as shown in general formula (I), or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a cocrystal thereof, an intermediate thereof, a preparation method therefor, and the use thereof in the preparation of a drug for treating diseases associated with WRN activity or expression level.

The invention relates to a phenyl-containing heterocyclic derivative regulator as well as a preparation method and application thereof. In particular, the present invention relates to a compound represented by general formula (XVI), a preparation method thereof, a pharmaceutical composition containing the compound, and an application of the compound as a regulator in the preparation of drugs for treating metabolic diseases and related diseases, each substituent in the general formula (XVI) being as defined in the specification # imgabs0 #

Provided are a pyrimidine polycyclic derivative inhibitor, a preparation method therefor and the use thereof. In particular, provided are a compound as shown in the general formula, a preparation method therefor, a pharmaceutical composition comprising the compound, and the use thereof in the treatment of cancers and other related diseases.

The invention provides a tetrahydropyridinopyrazole derivative and application thereof in medicine, and particularly relates to a compound shown in a general formula (I) or a stereoisomer, a tautomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or eutectic of the compound, and an intermediate and a preparation method of the tetrahydropyridinopyrazole derivative. The invention also relates to application in preparation of related medicines for treating diabetes mellitus. # imgabs0 #

Provided are a crystal form of a pyridopyrimidine derivative, a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Specifically disclosed are a crystal form of a compound of formula (I), a preparation method therefor, a pharmaceutical composition thereof and the use thereof.

The present invention provides a compound as shown in formula (I), and a pharmaceutically acceptable salt of the compound. The compound in the present invention exhibits a strong inhibitory effect on Lp(a) assembly, and can be used for treating cardiovascular diseases (CVD).

The invention relates to a battery monomer, a battery device and a power utilization device, the battery monomer comprises an electrode assembly and an electrolyte, and the electrode assembly comprises a positive pole piece and a negative pole piece; the positive pole piece comprises lithium-containing phosphate with an olivine structure; the negative pole piece comprises graphite particles; the electrolyte comprises a carboxylic ester solvent and a first additive, the thickness of the single-side negative electrode film layer is 50 microns to 75 microns, and the volume average particle size of the graphite particles is 8.5 microns to 13.5 microns; based on the mass of the electrolyte, the mass content of the carboxylic ester solvent is 8%-60%, the total mass content of the first additive is 3%-10%, the first additive comprises 1, 3-propane sultone with the mass content larger than or equal to 0, an ethylene carbonate derivative with the mass content larger than or equal to 0 and vinylene carbonate with the mass content larger than or equal to 3%, and the ethylene carbonate derivative comprises a compound shown in the formula A. According to the invention, the rapid charging performance and the cycle performance of the battery monomer under high energy density can be improved. # imgabs0 # formula A

Disclosed in the present invention are a polycyclic derivative, and a preparation method therefor and the use thereof. In particular, the present invention relates to a compound represented by general formula (I) or a stereoisomer thereof, a preparation method therefor, a pharmaceutical composition comprising the compound, and the use thereof in the preparation of a drug for treating diseases. The compound has a structure as represented by formula (I).

Provided are diaminocyclopentyl substituted heteroaryl derivatives, the use thereof and a preparation method therefor. In particular, the present disclosure relates to compounds represented by formula (I)each substituent of which is defined in the description, and a preparation method therefor. The compounds can be used as PCSK9 inhibitors to prevent and / or treat PCSK9-mediated diseases and disorders.

The invention discloses a double-boron polycyclic compound for an organic electroluminescent device, and belongs to the technical field of organic electroluminescent materials. The double-boron polycyclic compound takes a spiro derivative as a center B atom to be directly bonded with N, O, S and Se, has relatively high singlet and triplet energy, proper HOMO and LUMO energy levels and relatively small singlet-triplet energy difference, and can be used as a luminescent material to be applied to an organic electroluminescent device to improve the luminous efficiency of the device and improve the color purity of the device. After the double-boron polycyclic compound is applied to an OLED as a luminescent material, the relative value of external quantum efficiency of a luminescent device is 105.6%-126.9%, the half-peak width is 22-29 nm, and compared with an OLED using BD01 as the luminescent material, the luminescent efficiency is obviously improved, the half-peak width of an emission spectrum is narrower, and the color purity is higher. The invention provides an MR-TADF material for improving the color purity of a blue light device.

To provide a compound which is a novel proline derivative, and to provide a pharmaceutical composition comprising the compound for the treatment of, for example, systemic sclerosis (SSc) and non-alcoholic steatohepatitis (NASH).SOLUTION: A pharmaceutical composition comprises, as a cGAS inhibitor, a compound which is a novel proline derivative encompassed by formula (I), or a prodrug, a pharmaceutically acceptable salt, or a stereoisomer of the compound.SELECTED DRAWING: None

The invention relates to an anti-static PP composite material and a preparation method thereof, and belongs to the technical field of high polymer materials. The antistatic PP composite material is prepared from the following components in parts by weight: 60 to 80 parts of PP resin, 10 to 20 parts of glass fiber, 0.1 to 0.5 part of a lubricant, 0.3 to 2 parts of a modified antistatic agent, 0.5 to 1.5 parts of a modified flame retardant and 0.2 to 0.8 part of an antioxidant, in the modified antistatic agent, an alkanolamide bond intermediate forms a conductive film, so that the resistivity is reduced, static dissipation is promoted, the material is endowed with lubricity, and the generation of static electricity is reduced; in addition, maleic anhydride forms a conductive layer and cooperates with quaternary ammonium salt to enhance hydrophilicity and accelerate charge transfer; a piperazine pyrophosphate derivative in the modified flame retardant and a phosphorus-nitrogen flame retardant cooperate to construct an expanded carbon layer to isolate a fire source and oxygen, so that the service life is prolonged; the anti-static PP composite material prepared by the invention not only has a good anti-static effect, but also has excellent flame-retardant and tensile properties.

The invention provides a high-temperature-resistant and high-salt-resistant nano imbibition agent as well as a preparation method and application thereof. The high-temperature-resistant and high-salt-resistant nano imbibition agent is prepared from amination modified mesoporous silica nanoparticles, nano cellulose, rhamnolipid, an anionic surfactant, citrate modified sodium zirconium phosphate, polyethylene glycol-b-polycaprolactone and a sulfydryl-carboxyl imidazoline derivative, therefore, the composite carrier formed by the aminated mesoporous silica nanoparticles and the nanocellulose has high mechanical strength and uniform dispersity, the oil-water interfacial tension is reduced through the synergistic effect of the rhamnolipid and the anionic surfactant, and the crude oil stripping efficiency is remarkably improved; the citrate modified sodium zirconium phosphate enables the salt resistance of the system to be greatly improved, and in a high-temperature and high-salt oil reservoir environment, the nano imbibition agent can remarkably improve the crude oil recovery rate and reduce the injection pressure and dosage; meanwhile, good adsorption resistance is achieved, and reservoir blockage is prevented; in addition, low-toxicity corrosion inhibition components protect equipment, and the service life of an oil well is prolonged.

Herbicidally active 3-phenylisoxazoline-5-carboxamides of cyclopentenylcarboxylic acid derivativesThe invention relates to 3-phenylisoxazoline-5-carboxamides of cyclopentenylcarboxylic acid derivatives of the general formula (I) and their agrochemically acceptable saltsand to their use in the crop protection sector.

Targeting lipid nanoparticles for nucleic acid delivery, In one embodiment, the targeting lipid nanoparticle includes an ionizable lipid, a cholesterol or cholesterol derivative, a helper lipid, a PEG lipid, a targeting lipid, and a nucleic acid. In other embodiments, the targeting lipid nanoparticle including an ionizable lipid, a cationic lipid, a cholesterol or cholesterol derivative, a helper lipid, a PEG lipid, a targeting lipid; and a nucleic acid. In other embodiments, the targeting lipid nanoparticle including an ionizable lipid, a cholesterol or cholesterol derivative, a helper lipid, a PEG lipid, a functionalized lipid; and a nucleic acid. In other embodiments, the targeting lipid nanoparticle including an ionizable lipid, a cationic lipid, a cholesterol or cholesterol derivative, a helper lipid, a PEG lipid, a functionalized lipid; and a nucleic acid. Also provided are kits for preparing targeting lipid nanoparticles and functionalized lipid nanoparticles for nucleic acid delivery.

The invention relates to the technical field of flame retardants, in particular to a phosphorus-nitrogen synergistic flame-retardant biomass flame retardant and application thereof. A conventional reaction type phosphorus-nitrogen flame retardant is huge in structure and large in steric hindrance and cannot be completely dissolved in an epoxy resin material system, the obtained flame-retardant epoxy resin is poor in transparency, and the mechanical property is greatly reduced. In order to solve the problems, the invention provides the phosphorus-nitrogen synergistic flame-retardant biomass flame retardant which is obtained by sequentially carrying out simple one-pot synthesis reaction on furfural and furfural derivatives with 2-amino-1, 3, 4-thiadiazole and DOPO, and the flame retardant is simple in structure, small in steric hindrance, easy to completely dissolve in epoxy resin, good in flame retardancy and good in flame retardance. The obtained flame-retardant epoxy resin is better in transparency, flame retardance and mechanical property.

A WRN helicase-inhibiting bis-heterocyclic derivative, a pharmaceutical composition containing same, and use thereof. Specifically, a compound represented by formula (I), a stereoisomer thereof, an optical isomer thereof, a pharmaceutically acceptable salt thereof, a crystal form thereof, an isotopic derivative thereof, a prodrug thereof, a metabolite thereof, a solvate thereof, or a hydrate thereof, a composition containing the compound, and use thereof as a WRN helicase inhibitor, which can be used to prepare a drug for treating WRN helicase-mediated diseases.

The invention discloses a polysubstituted pyrrolidine derivative represented by a general formula (I), a stereoisomer, a tautomer, a deuterated derivative or a pharmaceutically acceptable salt thereof, and a preparation method and application of the compound. The invention also relates to pharmaceutical compositions comprising these compounds, stereoisomers, tautomers, deuterated derivatives or pharmaceutically acceptable salts thereof, uses of the compounds as sodium channel subtype Nav1.8 inhibitors, and uses thereof in the treatment and prevention of pain-related diseases. # imgabs0 #

Provided in the present invention are a tetrahydropyridopyrazole derivative and use thereof in medicine. Specifically provided is a compound as shown in general formula (I) or a racemate, stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate thereof, a preparation method therefor, and use thereof in the preparation of a related drug for treating diabetes or obesity.

The invention discloses a Fe-MOF derivative / biochar nano composite material as well as a preparation method and application thereof, and belongs to the field of degradation of organic pollutants in a water body. The invention aims to solve the problems of unstable structure, easy agglomeration and the like at high temperature. The preparation method comprises the following steps: by taking an Fe-MOF derivative as a precursor and charcoal as a carrier material, carrying out in-situ synthesis on Fe-MOF, and carrying out high-temperature calcination on the surface of charcoal (BC). The metal carbon-based composite material prepared by the method shows excellent catalytic performance in catalytic degradation of tetracycline in a water body. Meanwhile, the prepared multiphase composite catalytic material has good stability and cycle performance.

The invention relates to the technical field of metal surface protection, and discloses a corrosion-resistant self-repairing metal fastener and a preparation method thereof.The corrosion-resistant self-repairing metal fastener comprises a zinc alloy matrix, a nanometer passivation layer, a slow-release corrosion-resistant layer and a self-repairing functional layer, and the nanometer passivation layer, the slow-release corrosion-resistant layer and the self-repairing functional layer sequentially wrap the zinc alloy matrix; the zinc alloy matrix consists of Al, Cu, Mg, Ce and Zn; the nano passivation layer adopts zinc phosphate / silane composite sol to construct a Si-O-P covalent bond network, and plasma is combined to graft epoxy groups to enhance the interface bonding strength; the slow-release anti-corrosion layer is used for loading a pH response type benzotriazole derivative through gradient aperture mesoporous silica, so that the dynamic controlled release of a corrosion inhibitor is realized; the self-repairing functional layer adopts a synergistic effect of a mechanical triggering type sulfydryl siloxane microcapsule and a pH triggering type EDTA chelating agent microcapsule to form a physical plugging-chemical passivation dual-mode repairing mechanism. Through four-stage cooperation of matrix modification, interface strengthening, slow-release regulation and control and intelligent repair, the corrosion resistance of the corrosion-resistant self-repairing metal fastener in a complex environment is remarkably enhanced.

The invention relates to the technical field of lithium-sulfur batteries, and discloses a sulfonyl ZIF-8 metal organic framework material, a lithium-sulfur battery diaphragm and a preparation method of the lithium-sulfur battery diaphragm. The preparation method of the sulfonyl ZIF-8 metal organic framework material comprises the following steps: dissolving a metal precursor and a mixed ligand in an organic solvent, and carrying out a coordination reaction under the action of organic alkali; solid is collected, washed and dried, and the sulfonic group ZIF-8 metal organic framework material is obtained. The metal precursor is soluble zinc salt; the mixed ligand comprises 2-methylimidazole and an imidazole derivative containing a sulfonic acid group. The sulfo group ZIF-8 metal organic framework material is prepared through a ligand doping strategy and is used for functional modification of the lithium-sulfur battery diaphragm; the shuttle behavior of lithium polysulfide (LiPS) can be effectively inhibited through the electrostatic repulsion effect of sulfonic acid groups and the synergistic effect of high-polarity adsorption sites; and the migration of Li < + > and the conversion efficiency of LiPS are remarkably promoted by an efficient ion transmission network, so that the cycle performance of the lithium-sulfur battery is improved.

The invention belongs to the technical field of medicines, and provides a cassia twig granular preparation as well as a preparation method and a product thereof. The cassia twig granule preparation is prepared from the following components in parts by weight: 35 to 50 parts of cassia twig granule extract dry paste and 50 to 105 parts of auxiliary materials, the auxiliary materials comprise lactose, beta-cyclodextrin and derivatives thereof, and citric acid. According to the invention, beta-cyclodextrin and derivatives thereof are used for replacing dextrin as an auxiliary material in the cassia twig granules, so that the interference problem of dextrin in drug detection is avoided, the formability, solubility and hygroscopicity of the cassia twig granule preparation are ensured, the stability of the preparation is improved, and the comprehensive performance is excellent.